Cargando…

Alternative initiations with 6-monthly paliperidone palmitate. A retrospective study

INTRODUCTION: 6-monthly paliperidone palmitate features an initiation regimen through 1-monthly paliperidone palmitate or 3-monthly paliperidone palmitate. Some patients do not have sufficient adherence to treatment and it is necessary at the clinical level to start directly with 6-monthly paliperid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benavente López, S., Bolaño Mendoza, S., Parra González, A., Lara Fernández, A., Herencias Nevado, A., Baca García, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434635/ http://dx.doi.org/10.1192/j.eurpsy.2023.1044

Ejemplares similares

Clinical experiences with 6-monthly paliperidone palmitate after 12 months of use. A retrospective study
por: Benavente López, S., et al.
Publicado: (2023)

Clinical experiences with 6-monthly paliperidone palmitate beyond the diagnosis of schizophrenia. A retrospective study
por: Benavente López, S., et al.
Publicado: (2023)

Alternative initiations with 6-monthly paliperidone palmitate. A descriptive study
por: Sobrino, O. C., et al.
Publicado: (2023)

Alternative initiation regimen of paliperidone palmitate long-acting injectable
por: Menendez Gil, I.E., et al.
Publicado: (2022)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
por: Escobedo-Aedo, P., et al.
Publicado: (2022)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

Alternative initiations of three-monthly and six-monthly paliperidone palmitate in a psychiatric hospitalization unit. About two clinical cases.
por: Juárez Calvo, V., et al.
Publicado: (2023)

Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2023)

PALIPERIDONE PALMITATE 6-MONTH FORMULATION FOR THE TREATMENT OF SCHIZOPHRENIA: A 4-MONTH FOLLOW-UP STUDY
por: Romero Guillena, S. L., et al.
Publicado: (2023)

Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
por: Fernández-Miranda, Juan J., et al.
Publicado: (2021)

Predictors of transition from paliperidone palmitate 1 and 3 months (PP1M & PPP3M) to paliperidone palmitate 6 months (PP6M)
por: Escobedo-Aedo, P. J., et al.
Publicado: (2023)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews, Maju, et al.
Publicado: (2019)

Relapse and frequency of injection of monthly paliperidone palmitate—A retrospective case–control study
por: Laing, Emily, et al.
Publicado: (2021)

Accidental Overdose of Paliperidone Palmitate
por: Ojimba, Chiedozie, et al.
Publicado: (2019)

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
por: Mathews, Maju, et al.
Publicado: (2018)

Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial
por: Bossie, Cynthia A., et al.
Publicado: (2011)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
por: Lopez, Alicia, et al.
Publicado: (2019)

Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia
por: Hargarter, L, et al.
Publicado: (2016)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia
por: Bell Lynum, Karimah S., et al.
Publicado: (2018)

Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate
por: Pai, Nagesh, et al.
Publicado: (2018)

Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder
por: Fu, Dong-Jing, et al.
Publicado: (2016)

Different onset patterns of monthly paliperidone palmitate in hospitalised patient diagnosed with schizophrenia
por: Herrera-Sánchez, Javier, et al.
Publicado: (2021)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
por: O’Donnell, Amy, et al.
Publicado: (2021)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

Effects of Paliperidone Palmitate on Coagulation: An Experimental Study
por: Yılmaz, Enver Demirel, et al.
Publicado: (2014)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder
por: Bossie, Cynthia A., et al.
Publicado: (2017)

Paliperidone palmitate-induced enuresis: a case report
por: Cruz, S., et al.
Publicado: (2022)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa, Jennifer Kern, et al.
Publicado: (2012)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash, Abigail I, et al.
Publicado: (2019)

A case report of pregnancy and paliperidone palmitate 3‐monthly long‐acting injection
por: de Azevedo Avelar, Rita, et al.
Publicado: (2020)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
por: El Khoury, Antoine C, et al.
Publicado: (2021)

Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions. 60 months of follow-up
por: Romero Guillena, S.L., et al.
Publicado: (2022)

Budget impact of introducing once-every-6-months paliperidone palmitate in US health care plans
por: Phelps, Hilary, et al.
Publicado: (2023)

Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY
por: Potkin, Steven G., et al.
Publicado: (2017)

Population Pharmacokinetics of Paliperidone Palmitate (Once‐Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia
por: Shimizu, Hiroko, et al.
Publicado: (2019)

Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs
por: Di Lorenzo, Rosaria, et al.
Publicado: (2022)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
por: Einarson, Thomas R, et al.
Publicado: (2012)

Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions and emergency room visits. 66 months of follow-up
por: Romero Guillena, S. L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t5tm5a0b6dg5f76p85i4ldkdek